- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07945275
A Superiority Study of Model-Guided Optimized Dosing Versus Empirical Dosing of Piperacillin/Tazobactam in the Treatment of Community-Acquired Pneumonia in Elderly Patients
A Randomized Superiority Study Comparing Model-Guided Optimized Dosing With Empirical Dosing of Piperacillin/Tazobactam in Elderly Patients With Community-Acquired Pneumonia
This study tests a new way to give an antibiotic to older adults with pneumonia. Pneumonia is a lung infection.
Piperacillin-tazobactam is an antibiotic. Doctors often use it to treat pneumonia in older adults. Right now, doctors usually give this drug every 8 hours. They let it drip into the vein over 3 hours.
But early research suggests a different schedule may work better. This study will test giving the drug every 6 hours. The drip will last 4 hours. Researchers think this may help the drug fight germs better.
The study will compare the usual schedule with the new schedule. Participants will join one of two groups. One group will get the usual schedule. The other group will get the new schedule.
Researchers will check how well the drug works. They will also watch for side effects. They want to find the safest and most helpful way to give this drug.
Adults aged 65 and older with community-acquired pneumonia can join. Community-acquired pneumonia is a lung infection that starts outside of a hospital.
Studie Overzicht
Toestand
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Wei Zhao
- Telefoonnummer: +8653188383308
- E-mail: zhao4wei2@hotmail.com
Studie Locaties
-
-
Shandong
-
Jinan, Shandong, China, 250000
- Werving
- Shandong Provincial Public Health Clinical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥ 65 years;
- Clinically diagnosed or highly suspected community-acquired pneumonia (CAP). CAP clinical diagnostic criteria: All three of the following must be met:
Onset in the community setting;
At least one of the following clinical manifestations:
New-onset cough, sputum production, or worsening of pre-existing respiratory symptoms, with or without purulent sputum, chest pain, dyspnea, or hemoptysis; Fever; Signs of pulmonary consolidation and/or moist rales; Peripheral white blood cell count > 10×10⁹/L or < 4×10⁹/L, with or without left shift; Chest imaging showing new patchy infiltrates, lobar/segmental consolidation, ground-glass opacities, or interstitial changes, with or without pleural effusion.
For patients aged ≥ 65 years with a body temperature < 38°C, the presence of clear clinical signs of pneumonia and abnormal chest X-ray findings will also be considered meeting the inclusion criteria.
- At least one of the following risk factors for drug-resistant pathogens:
Comorbidities such as chronic cardiopulmonary disease, diabetes mellitus, renal failure, etc.; Use of broad-spectrum antibiotics within the past 3 months; History of repeated hospitalizations or residence in a long-term care facility;
- Patients are required to initiate intravenous empiric antimicrobial therapy, and piperacillin-tazobactam is considered appropriate empiric treatment.
- Expected length of hospital stay ≥ 72 hours;
- Signed informed consent form.
Exclusion Criteria:
- Highly suspected or confirmed fungal pneumonia or viral pneumonia;
- Concurrent use of broad-spectrum antibiotics with similar antibacterial spectra, including cefoperazone-sulbactam, imipenem-cilastatin, meropenem, biapenem and others;
- Patients with severe allergy to β-lactams and history of severe adverse reactions;
- End-stage diseases with expected survival time shorter than the treatment course, such as advanced malignant tumors and end-stage organ failure;
- Severe renal insufficiency with creatinine clearance <40 mL/min, or patients receiving continuous renal replacement therapy (CRRT);
- Any other conditions deemed ineligible for enrollment by investigators.
Post-randomization exclusion criteria:
- Isolated fungal infection;
- Isolated viral infection;
- Patients with confirmed pathogenic bacteria resistant to piperacillin-tazobactam (PIP/TAZO) during the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: guideline-based conventional dosing
|
Control arm (guideline-based conventional dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 3-hour intravenous infusion every 8 hours (q8h), for a total treatment course of 5-14 days. |
|
Experimenteel: Model-guided optimized dosing
|
Intervention arm (model-guided optimized dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 4-hour intravenous infusion every 6 hours (q6h), for a total treatment course of 5-14 days. This arm adopts increased dosing frequency and prolonged infusion duration compared with the control arm. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
The proportion of patients achieving the predefined pharmacodynamic (PD) target.
Tijdsspanne: up to 1 month
|
up to 1 month
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Clinical improvement rate after 3 days of empiric therapy
Tijdsspanne: Day 3
|
Day 3
|
|
Length of hospital stay
Tijdsspanne: through hospital discharge, an average of 2 weeks
|
through hospital discharge, an average of 2 weeks
|
|
Treatment success rate
Tijdsspanne: through hospital discharge, an average of 4 weeks
|
through hospital discharge, an average of 4 weeks
|
|
Adverse event (AE) incidence rate
Tijdsspanne: through end of study-drug treatment, an average of 7 days
|
through end of study-drug treatment, an average of 7 days
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Luchtweginfecties
- Infecties
- Ziekten van de luchtwegen
- Longziekten
- Longontsteking
- Zwavelverbindingen
- Organische chemicaliën
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Therapeutica
- Routes voor het toedienen van geneesmiddelen
- Drugstherapie
- Amides
- Penicilline g
- bèta-lactams
- Lactams
- Sulfonen
- Penicillaninezuur
- Ampicilline
- Penicillines
- Tazobactam
- Piperacilline
- Injecties
Andere studie-ID-nummers
- SDU-2026-elePIP-001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data (IPD) will not be shared due to patient privacy and confidentiality regulations, and the lack of specific informed consent for public data sharing.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .